LightIntegra Technology Inc., a privately funded medical diagnostics company, has appointed William “Bill” Dubiel as President & CEO effective March 13, 2017. Dubiel was also appointed to the board of directors LightIntegra. Paul Geyer will continue to serve as the Executive Chairman of LightIntegra.
“This is the perfect time for Bill to become LightIntegra’s next President and Chief Executive Officer. We’ve selected a very strong leader at a time when LightIntegra is ready to take the leap to commercialize the ThromboLUX product,” said Geyer. “Our next CEO needs to be an expert at commercially launching products into the market with early US focus while building a world class commercial organization with a heightened sense of urgency. Bill is unique in his ability to translate vision and strategy into world-class execution, building teams and driving high performance. His immediate focus will be on building a customer-centric sales organization and putting the systems and processes in place to commercialize our novel technology.”
Dubiel joins LightIntegra from Personal Genome Diagnostics, where he has been the Chief Commercial Officer. He has held senior level positions at CyVek, Ventana, Roche, Bayer and Chiron Diagnostics. He has led many commercial organizations and successfully launched 5 uniquely different disruptive technologies in the clinical and life science segment during his career.
“I am excited to lead LightIntegra at this pivotal time. LightIntegra has developed a unique testing system that improves quality of care, enhances productivity and lowers the cost of healthcare. These are the key ingredients of success in the healthcare market today and I am fortunate to lead a great team of people and bring this technology to healthcare providers and ultimately the patients they serve worldwide,” said Dubiel.
LightIntegra Technology was launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer. LightIntegra created ThromboLUX, a rapid in vitro test that provides size distribution information for microparticles in blood products. As a routine test for platelet concentrates, ThromboLUX may identify which platelet units would be best suited for prophylaxis and which units are better suited for therapeutic use.
LightIntegra recently closed a new round of financing, raising $##Subscribers, please login to read deal details. Not yet a subscriber? Subscribe today to see our research on this deal and all other subscriber ONLY deals## million from private investors.
photo credit: LightIntegra Technology
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Spring Lane Capital Fund I final closes at US $156.5M - December 10, 2019
- Synaptive Medical closes US $25M financing led by Linamar and Audible Capital - December 10, 2019
- Icentia secures financing led by Crédit Mutuel Equity - December 9, 2019